Trial Profile
Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinsons Disease: a Multi-center Placebo-controlled Trial.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 08 Apr 2022
Price :
$35
*
At a glance
- Drugs Rivastigmine (Primary)
- Indications Hallucinations; Parkinson's disease
- Focus Therapeutic Use
- Acronyms CHEVAL
- 04 Oct 2018 Status changed from recruiting to discontinued due to slow enrollment and insufficient funds
- 04 Jan 2018 Planned End Date changed from 1 Dec 2020 to 1 Dec 2022.
- 04 Jan 2018 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2021.